In this one-hour webinar, sleep physician-presenters explore how to better identify, assess, and manage residual EDS in 2026—moving beyond the AHI to focus on real-world functional outcomes, patient-reported symptoms, and emerging treatment strategies.
The company reported $714 million in preliminary 2024 revenue for Wakix and outlined 2025 catalysts, including pitolisant for idiopathic hypersomnia and Pitolisant-HD for narcolepsy.
The FDA has expanded the approval of a narcolepsy drug, previously approved for adults, to now include children aged 6 and older.
It’s easy to reach for extra doses of caffeine to boost energy, but that extra boost may be doing more harm than good, a dietician says.
Read More
AXS-12, a norepinephrine reuptake inhibitor, significantly reduced cataplexy attacks in narcolepsy patients in the ENCORE phase 3 trial, demonstrating long-term efficacy, safety, and improvements in excessive daytime sleepiness and cognition.
Read More
The research found significant associations between sleep quality and the “Big Five” personality traits: openness, conscientiousness, extraversion, agreeableness, and neuroticism.
Read More
During the quarter, Lumryz saw increased patient uptake, expanded to pediatric use, and secured a legal victory affirming its clinical superiority, as the company continues its phase 3 trial in idiopathic hypersomnia.
Read More
Older adults with daytime sleepiness were more likely to develop a condition that occurs before dementia develops.
Read More
Top-line results show improvements on excessive daytime sleepiness and key polysomnography outcomes.
Read More
Axsome Therapeutics will present findings on solriamfetol’s impact on excessive daytime...
Read More
A survey by the American Academy of Sleep Medicine reveals the strategies Americans use to combat daytime sleepiness
Read More
Researchers say the brain-based test could predict whether someone is safe enough to drive or has the mental capacity to sit for an exam.
Read More
The AASM survey highlights how daytime sleepiness affects work productivity, mental health, and personal relationships.
Read More
In non-human primate models, oral administration of ORX142 promoted sustained increases in wakefulness at the lowest dose tested.
Read More
Axsome Therapeutics is set to unveil data on AXS-12 and solriamfetol at Sleep Europe 2024, including results from a phase 3 trial in narcolepsy and solriamfetol’s impact on EDS.
Read More
For those living with narcolepsy or are pre-diagnosis, mischaracterizations can result in stigma and contribute to the extended average delay in diagnosis.
Read More
Preclinical data on ORX142, showing its effectiveness in promoting wakefulness at low doses in non-human primates, will be presented at Sleep Europe 2024.
Read More
The merged company will focus on advancing NLS’s dual orexin agonist platform, while continuing development of Kadimastem’s treatments for neurodegenerative diseases and diabetes.
Read More